Bluejay Investor Presentation Deck slide image

Bluejay Investor Presentation Deck

SymphonyTM System Commercial Advantages¹ v. Central Lab Analyzer Systems for IL-6 ●●● Near Patient Test System Size Sample Type Advantages Separate Sample Processing Step Total Turnaround Time Requires Dedicated Personnel* System/Infrastructure Cost NPV2 for IL-6 Assay *(Phlebotomist/MedTech) bluejay DIAGNOSTICS Bluejay Symphony™ Near Patient Desktop Whole Blood No ~20 minutes No $ 98% Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Beckman, Siemens, Roche Central Lab Very Large Serum/Plasma Yes 4-48hr³ Yes $$$ 78.6-92.9%4 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 14
View entire presentation